Efficacy News and Research

RSS

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Today Biogen Idec announced that the European Commission (EC) has granted marketing authorization for PLEGRIDY (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).

25 Jul 2014

Genticel provides update on patents granted in the USA and Asia

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, provides an update on patents that have recently enriched its intellectual property estate.

25 Jul 2014

Malvern acquires MicroCal business and Affinity Biosensors' Archimedes product

Malvern Instruments Ltd (Malvern, UK) has today announced that it has completed the acquisition of MicroCal from GE Healthcare Life Sciences and has also purchased the Archimedes particle characterization system from Affinity Biosensors LLC (Santa Barbara, CA).

25 Jul 2014

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).

25 Jul 2014

New treatment fights respiratory syncytial virus in children

Researchers at Le Bonheur Children's Hospital and the University of Tennessee Health Science Center announced results of a clinical trial of a new drug shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV).

25 Jul 2014

HPV vaccination may be effective in reducing abnormal Pap test results even after sexual debut

Minority women who received the Human Papillomavirus Vaccination (HPV) even after becoming sexually active had lower rates of abnormal Pap test results than those who were never vaccinated.

25 Jul 2014

Capsazepine shows dramatic tumor shrinkage without damaging surrounding tissues

Mouse models of human oral cancer treated with an agent called capsazepine showed dramatic tumor shrinkage without damage to surrounding tissues, researchers from the School of Dentistry and School of Medicine at The University of Texas Health Science Center at San Antonio found.

24 Jul 2014

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers.

24 Jul 2014

Co-targeting strategies suggested for EGFR-TKI resistance in NSCLC

Researchers have identified additional resistance mechanisms that could be targeted to improve the efficacy of irreversible epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small-cell lung cancer harbouring both EGFR and T790M mutations.

23 Jul 2014

Tackling hepatitis C: an interview with Gaston Picchio, Global Hepatitis Disease Area Leader at Janssen

Gaston Picchio outlines the major findings of the recent report published by The Economist Intelligence Unit (EIU): ‘Tackling hepatitis C: Moving towards an integrated policy approach’

23 Jul 2014

Activity level predicts how well patients recover from injuries after treatment

According to a literature review in the July issue of the Journal of the American Academy of Orthopaedic Surgeons, patients' activity level is a strong predictor for how well they will do with certain treatments and how well they recover from injuries after treatment. Patients are encouraged to ask their orthopaedic surgeon if activity level is an important factor in their treatment decision.

23 Jul 2014

Advaxis, MedImmune team up for immuno-oncology clinical trial

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca.

23 Jul 2014

Targeting CXCR4–CXCL12–CXCR7 axis combats mTOR inhibitor resistance in renal cancer

There is considerable crosstalk between the CXCR4–CXCL12–CXCR7 axis and the mammalian target of rapamycin pathway in human renal cell carcinoma, and targeting the axis may overcome drug resistance to mTOR inhibitors, researchers suggest.

22 Jul 2014

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

22 Jul 2014

Long-acting inhaled combination therapy best for COPD

The combination of a long-acting β22-agonist and an inhaled corticosteroid may be the best choice for some patients with chronic obstructive pulmonary disease who need more than short-acting bronchodilators, suggest the results of a Cochrane Collaboration network meta-analysis.

22 Jul 2014

Study confirms effectiveness of EKF PointMan technology for isolating low-level DNA mutations in blood

EKF, announces that the latest results from its collaboration with the Institute of Life Sciences at the University of Swansea, UK.

From EKF Diagnostics 22 Jul 2014

α1-adrenoceptor blockade improves nocturia and sleep quality

Treatment with an α1-adrenoceptor antagonist drug is associated with significant improvements in nocturia, sleep quality and lower urinary tract symptoms in women with voiding symptoms, study findings show.

21 Jul 2014

CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that China's Food and Drug Administration has approved the Company's application to conduct a Phase II clinical trial in triple-negative breast cancer (TNBC) patients in China for its proprietary drug candidate, ENMD-2076.

21 Jul 2014

Early-career physicians receive National Psoriasis Foundation fellowship to study psoriasis

Twelve residents and medical students each received a one-year, $50,000 National Psoriasis Foundation fellowship to study psoriasis.

21 Jul 2014

Researchers identify group of cells in brain that plays important role in Down syndrome

Researchers from UC Davis School of Medicine and Shriners Hospitals for Children - Northern California have identified a group of cells in the brain that they say plays an important role in the abnormal neuron development in Down syndrome.

21 Jul 2014

Efficacy News and Research

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Genticel provides update on patents granted in the USA and Asia

Malvern acquires MicroCal business and Affinity Biosensors' Archimedes product

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

New treatment fights respiratory syncytial virus in children

HPV vaccination may be effective in reducing abnormal Pap test results even after sexual debut

Capsazepine shows dramatic tumor shrinkage without damaging surrounding tissues

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

Co-targeting strategies suggested for EGFR-TKI resistance in NSCLC

Tackling hepatitis C: an interview with Gaston Picchio, Global Hepatitis Disease Area Leader at Janssen

Activity level predicts how well patients recover from injuries after treatment

Advaxis, MedImmune team up for immuno-oncology clinical trial

Targeting CXCR4–CXCL12–CXCR7 axis combats mTOR inhibitor resistance in renal cancer

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Long-acting inhaled combination therapy best for COPD

Study confirms effectiveness of EKF PointMan technology for isolating low-level DNA mutations in blood

α1-adrenoceptor blockade improves nocturia and sleep quality

CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

Early-career physicians receive National Psoriasis Foundation fellowship to study psoriasis

Researchers identify group of cells in brain that plays important role in Down syndrome

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News